Reuters logo
BRIEF-Horizon Pharma Plc to acquire River Vision Development Corp
2017年5月8日 / 中午11点37分 / 6 个月前

BRIEF-Horizon Pharma Plc to acquire River Vision Development Corp

May 8 (Reuters) - Horizon Pharma Plc:

* Horizon Pharma Plc announces agreement to acquire River Vision Development Corp and teprotumumab (rv001), a biologic in late-stage development for rare eye disease

* Horizon Pharma Plc - pivotal trial of teprotumumab in thyroid eye disease (ted) expected to begin in second half of 2017

* Horizon Pharma Plc - deal for upfront cash payment of $145 million

* Horizon Pharma - Horizon anticipates a potential peak annual sales opportunity for Teprotumumab, if approved, in excess of $250 million in United States Source text for Eikon: Further company coverage:

我们的标准:汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below